Drug Approval | January 19, 2024
Zydus and Synthon inks licensing and supply agreement for Palbociclib Tablets for US market
Synthon will be responsible for obtaining US regulatory approval for Palbociclib Tablets
Synthon will be responsible for obtaining US regulatory approval for Palbociclib Tablets
The primary goal of this joint venture is to develop and commercialise novel cell therapy products for major unmet medical needs in the United States, Japan, and EU regions
The deal includes upfront payments, milestone payments and ongoing royalties
IntoCell will provide proprietary drug-linker technologies using their Ortho-Hydroxy Protected Aryl Sulfate
Innovent also obtains an exclusive option to license in the future development, manufacturing and commercialization rights of SGB-3908
Innovent will supply sintilimab for the collaborated clinical trial
10+ emerging markets, Japan & ANZ transition in final phase
The exclusive agreement also includes development, regulatory, and commercialization milestone payments based on the successful outcome
First published clinical trial using live biotherapeutic candidate in Covid-19 patients suggests role in improving outcomes
C-CAR031 is based on a novel GPC3-targeting CAR-T (AZD5851) designed by AstraZeneca using their transforming growth factor-beta receptor II
Subscribe To Our Newsletter & Stay Updated
